This week we focus on pharmaceutical litigation: a ruling that failure-to-warn claims brought against generic drug makers are pre-empted by federal law, a look at why drug manufacturers who comply with FDA labeling regulations are granted a rebuttable presumption that their labeling is adequate, and some practical pointers for litigators of product-liability cases.
Product Liability & Toxic Torts
New Jersey Law Journal
December 7, 2011
This article requires premium access
This article requires premium access to The New Jersey Law Journal. Please sign in or subscribe to read the full text.